CN101168564A - Human antibiotic peptide and use for derivative thereof - Google Patents
Human antibiotic peptide and use for derivative thereof Download PDFInfo
- Publication number
- CN101168564A CN101168564A CNA2007100663029A CN200710066302A CN101168564A CN 101168564 A CN101168564 A CN 101168564A CN A2007100663029 A CNA2007100663029 A CN A2007100663029A CN 200710066302 A CN200710066302 A CN 200710066302A CN 101168564 A CN101168564 A CN 101168564A
- Authority
- CN
- China
- Prior art keywords
- peptide
- lys
- gly
- antibacterial peptide
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Abstract
The invention relates to human antimicrobial peptide and the purpose of the derivant thereof. The human antimicrobial peptide has amino acid sequences chosen from a SEQ ID NO: 1 listing, and also comprises function equivalents obtained by substitution, cyclization, change from L-amino acid into D-amino acid, lacunae or addition of respective amino acid in amino acid sequence polypeptide. Compared with other source base antimicrobial polypeptide, the human antimicrobial peptide has the advantages that the structure is simple, the artificial synthesis is convenient, and the human antimicrobial peptide is applied to human body non-antigenicity. The human antimicrobial peptide and the derivant of the human antimicrobial peptide of the invention has the remarkable functions of inhibiting bacteria and funguses from growing, thus the human antimicrobial peptide can be used to prepare anti-microorganism infective preparation.
Description
Technical field
The present invention relates to the purposes of human antibiotic peptide and derivative thereof, be specifically related to people's semenogelin degrade aminoacid sequence, nucleotide coding sequence and their antibacterial application of little peptide SgI-29 and derivative thereof.
Background technology
Infectious diseases is the one of the main reasons that threatens the human life always, and the eighties of last century microbiotic thirties is found and is widely used in clinical treatment, has saved countless patients' life.Because the antibiotic a large amount of uses of tradition have caused increasing rapidly of multidrug resistant disease pathogenic microorganism.Therefore demanding developing new antibiotic now urgently tackles pathogenic micro-organism resistance serious day by day in the world wide.
Antibacterial peptide (having another name called peptide antibiotics) is extensive in distributed in nature, is the endogenous material of resisting exogenous infection that organism produces, and goes through millions of years and seldom produces tolerance, has characteristics such as effect is rapid, powerful, wide spectrum.Thereby in it is found, just caused (the Koczulla AR that attractes attention of pharmacy circle and high-tech biological industry circle, Bals R, 2003.Antimicrobialpeptides:current status and therapeutic potential.Drugs 63,389-406).
Antibacterial peptide is distributed in batrachians, insect, plant and the Mammals widely.Discover that antibacterial peptide content in amphibian animal skin is especially abundant, people have found nearly thousand antibacterial peptides (can retrieve at http://www.bbcm.univ.trieste.it/～tossi/pag1.htm) from nature over more than 30 year, wherein there be more than 800 from batrachians skin (mainly being batrachia) (Apponyi MA, et al., 2004.Host-defence peptides of Australian anurans:structure, mechanism of action and evolutionary significance.Peptides 25,1035-1054).
Since the microbiotic invention, the mankind have obtained bigger achievement in control and treatment infected by microbes, but along with antibiotic lasting use at present, the microorganism resistance has become the significant problem in the infected by microbes control at present, to such an extent as to the certain micro-organisms bacterium has not been controlled a line material of killing.As in clinical drug therapy, it all is worldwide clinical difficult problems at present that the staphylococcus of vancomycin resistance, faecalis and other Gram-negatives catch.Three classes cause that mainly strong resistance has also appearred in meningitic bacterium clinically, anti-penicillin, paraxin meningococcus, and streptococcus pneumoniae, antibiotic streptococcus pneumoniae also extensively occurs the antagonism cephalosporin.Therefore the discovery of new class antimicrobial material and development have become the task of top priority and international focus.Compare with present widely used microbiotic, peptide antibiotics has lot of advantages: as when the least action concentration, fast and the killing microorganisms of wide spectrum (comprising clinical anti-medicine bacterium at present), fungi also there is restraining effect, the resistant strain generative nature is little, all effective to local infection and systemic infection, just becoming the new class microbiotic, its development is subjected to extensive attention (Brogden KA at present, 2005.Antimicrobial peptides:pore formers or metabolic inhibitors in bacteria? Nat.Rev.Microbiol.3,238-250).
Human antibiotic peptide is one of focus of research always, it does not have antigenicity, therefore easier as medicine use (DeSmet K, Contreras R, 2005.Human antimicrobial peptides:defensins, cathelicidins and histatins.Biotechnol.Lett.27,1337-1347).
Summary of the invention
An object of the present invention is to provide human antibiotic peptide and derivative thereof, has the beneficial features that simple in structure, synthetic is convenient, be applied to the human body no antigen, another object of the present invention provides the purposes of human antibiotic peptide and derivative thereof, and it has the effect of significant inhibition bacterium and fungal growth.
The object of the present invention is achieved like this:
The present invention relates to a kind of human antibiotic peptide, separate obtaining its aminoacid sequence following (SEQ ID NO:1) from the healthy male semen liquefaction:
Histidine-asparagine-lysine-GLN-glutamic acid-glycine-arginine-aspartic acid-histidine-aspartic acid-lysine-serine-LYS-GLY-HIS-PHE-histidine-arginine-valine-valine-isoleucine-histidine-HIS-LYS-Gly-Gly-lysine-Ala-His (His Asn Lys Gln Glu Gly Arg Asp His Asp Lys Ser Lys Gly His Phe His Arg Val Val IleHis His Lys Gly Gly Lys Ala His).
Human antibiotic peptide of the present invention comprises that indivedual amino acid whose replacements in the aforementioned polypeptides, cyclisation, L-type amino acid become D-type amino acid, disappearance or adding and the polypeptide of the function equivalent that obtains.
Promptly substitute and have the antibacterial peptide of anti-microbial activity derived from the isolating human antibiotic peptide amino-acid residue of above-mentioned human antibiotic peptide, described antibacterial peptide has and is selected from the aminoacid sequence shown in the sequence table SEQ ID NO:2: His Asn Lys Gln Glu GlyLys Asp His Asp Lys Ser Lys Gly His Phe His Arg Val Val Ile His His Lys Gly Gly Lys Ala His.
Can also be derived from a plurality of aminoacid deletion of above-mentioned human antibiotic peptide and have the antibacterial peptide of anti-microbial activity that described antibacterial peptide has and is selected from the aminoacid sequence shown in the sequence table SEQ ID NO:3: Lys Gln Glu Gly Arg Asp His Asp LysSer Lys Gly His Phe His Arg Val Val Ile His His Lys Gly Gly Lys.
Human antibiotic peptide provided by the invention, its preparation method can be mechanochemical methods, also the encoding gene of antibacterial peptide can be cloned on the carrier, express the back then and obtain in host cell.Wherein expression vector can be a kind of in plasmid or the virus.Host cell can be a prokaryotic cell prokaryocyte, comprises intestinal bacteria or subtilis etc., and host cell also can be an eukaryotic cell, comprises yeast cell, vegetable cell, insect cell or mammalian cell etc.The antibacterial peptide of preparation can be identified by mass spectrum.
The separation method of human antibiotic peptide of the present invention separates antibacterial peptide and has the aminoacid sequence shown in the SEQ ID NO:1.
The preparation method of human antibiotic peptide of the present invention and derivative thereof adopts mechanochemical method synthetic.
A kind of isolating nucleotide sequence or its complementary sequence, described nucleotide sequence coded antibacterial peptide recited above.
A kind of construction, described construction contain and have the nucleotide sequence that is selected from the aminoacid sequence shown in the sequence table SEQ ID NO:3.
A kind of cell, described cell contain peptide recited above, top described nucleotide sequence or construction recited above.
The method of described antibacterial peptide above the preparation, this method comprises:
(1) under the condition that is fit to peptide expression recited above, cultivates cell recited above;
(2) isolate antibacterial peptide recited above.
The purposes of human antibiotic peptide of the present invention and derivative thereof, the application in the medicine of preparation anti-microbial infection of described antibacterial peptide and derivative thereof.
In order to further investigate the structure-function relationship of this human antibiotic peptide of the present invention and derivative thereof, utilize full-automatic polypeptide synthetic instrument to synthesize one group of polypeptide, to study.
With the SgI-29 with following amino acid sequences of preparation, SgI-29R7K and SgI-25 antibacterial peptide are that example is narrated below:
SgI-29(SEQ?ID?NO：1)：
His?Asn?Lys?Gln?Glu?Gly?Arg?Asp?His?Asp?Lys?Ser?Lys?Gly?His?Phe?His?Arg?Val?Val?Ile?HisHis?Lys?Gly?Gly?Lys?Ala?His
SgI-29R7K(SEQ?ID?NO：2)：
His?Asn?Lys?Gln?Glu?Gly?Lys?Asp?His?Asp?Lys?Ser?Lys?Gly?His?Phe?His?Arg?Val?Val?Ile?HisHis?Lys?Gly?Gly?Lys?Ala?His
SgI-25(SEQ?ID?NO：3)：
Lys?Gln?Glu?Gly?Arg?Asp?His?Asp?Lys?Ser?Lys?Gly?His?Phe?His?Arg?Val?Val?Ile?His?His?LysGly?Gly?Lys
Utilize the agar diffusion experiment to detect the bacteriostatic activity of polypeptide.The result shows that synthetic antibacterial peptide of the present invention has strong fungicidal activity.
Antibacterial peptide function equivalent to aminoacid deletion derivative in the polypeptide has also carried out preparation and biological activity determination equally, and the result shows that these polypeptide also have fungicidal activity preferably.
Beneficial effect of the present invention is: human antibiotic peptide and derivative thereof have the effect of significant inhibition bacterium and fungal growth.Compare with other alkaline antimicrobial polypeptide of originating, that this human antibiotic peptide has is simple in structure, synthetic convenient, be applied to the beneficial features of human body no antigen.
Description of drawings
Fig. 1 is the SP-Sepharose ion exchange chromatography figure of human antibiotic peptide of the present invention.
Fig. 2 is the G-25 sieve chromatography figure of human antibiotic peptide of the present invention.
Fig. 3 is the Mono-S ion exchange chromatography figure of human antibiotic peptide of the present invention.
Fig. 4 is the anti-phase C18 column chromatography of the HPLC of human antibiotic peptide of the present invention figure.
Fig. 5 is the mass spectrum at the anti-phase C18 column chromatography of human antibiotic peptide HPLC of the present invention III peak.
Fig. 6 is the nucleotide sequence of human antibiotic peptide SgI-29 gene of the present invention.
Fig. 7 is the aminoacid sequence of human antibiotic peptide SgI-29 of the present invention.
Fig. 8 is the mass spectrum of synthetic human antibiotic peptide SgI-29 of the present invention.
Embodiment
1, the separation and purification of human antibiotic peptide:
The normal people after ascetic 3-7 days the masturbation extracting extract in the dry disinfection measuring cup, after the room temperature liquefaction, through sperm microorganism sound attitude area of computer aided automatic analysis system (model: CASAS-QH-III, Beijing Tsing Hua Tong Fang product) determine the normal sample of the every index of sperm in 10000 rev/mins of centrifugal 10 minutes separated sperms and seminal fluid, carefully collect supernatant liquor put-20 ℃ standby.
The first step: SP-Sepharose ion-exchange: normal people's seminal fluid (n=40) of Huo Deing is splined on and uses 50mM Na2HPO4-NaH2PO4 in advance as stated above, PH=7.4 damping fluid equilibrated SP-Sepharose (Pharmacia product) cationic exchange coloum (130mm is long, diameter 20mm).After finishing, last sample carries out linear elution with 0-0.5M NaCl.Every pipe is collected 3ml.Bacteriostatic activity detects and shows that the 58-131 pipe has very strong fungicidal activity.Merge 58-131 pipe frost drying and concentrate, see accompanying drawing 1.
Second step: molecular sieve Sephadex G-25 chromatography: after the first step freeze-drying concentrating sample dissolves with the Milli-Q ultrapure water, be splined on and use 50mM Tris-HCl in advance, pH8.8 damping fluid equilibrated AKTA HiPrepTM G-25 desalting column (26/10, the Pharmacia product), used instrument is AKTA Explore 100 (an Amersham Biosciences product).Collect the II peak and carry out frost drying and concentrate, referring to accompanying drawing 2.
The 3rd step: Mono-S ion-exchange: after the second step freeze-drying concentrating sample dissolves with the Milli-Q ultrapure water, be splined on and use 50mM Tris-HCl in advance, pH8.8 damping fluid equilibrated Mono-S cationic exchange coloum (1ml, HR5/5, the Pharmacia product), used instrument is AKTAExplore 100 (an Amersham Biosciences product).Collect the VII peak, see accompanying drawing 3.
The 4th step: reverse phase HPLC: through Mono-S cation exchange column chromatography gained VII peak Yi Shui (containing 0.1% trifluoroacetic acid): the elution system that second fine (containing 0.1% trifluoroacetic acid) constitutes is carried out gradient elution, collect the III peak and be the people's semenogelin I derived peptide that contains anti-microbial activity, see accompanying drawing 4.
Contain the evaluation of people's semenogelin I derived peptide of anti-microbial activity:
The first step: the determined amino acid sequence at reverse phase HPLC III peak: adopt full-automatic Protein Sequencer (model: 491, ABI company product) to measure the aminoacid sequence structure.The result shows that the aminoacid sequence at reverse phase HPLC III peak is: His Asn Lys Gln Glu Gly Arg Asp His Asp Lys Ser.
Second step: fast atom bombardment mass spectroscopy(FABMS) method (Fast atom bombardment mass spectrometry, FAB-MS) determining molecular weight: with glycerine: m-nitrobenzyl alcohol: methyl-sulphoxide (1: 1: 1, V: V: V, volume ratio) is substrate, Cs+ is as projectile, electric current is 1mA, and emission voltage is 25Kv.The result shows that reverse phase HPLC III peak contains 4 molecules, and their molecular weight is respectively 3377.17 dalton, 3850.67 dalton, 5117.64 dalton and 5174.18 dalton, sees accompanying drawing 5.
The 3rd step: the evaluation of people's semenogelin I derived peptide: the result that the reverse phase HPLC III peak aminoacid sequence His Asn Lys Gln Glu Gly Arg Asp His Asp Lys Ser of mensuration carries out the BLAST analysis discloses the degraded that it derives from people's semenogelin I, is the derived products of people's semenogelin I.It is that 3377.17 daltonian polypeptide derive from into acquaintance's semenogelin I that the mass spectral accurate molecular weight of FAB-MS is measured the proof molecular weight, and its shearing site is into the 85th and the 113rd of acquaintance's semenogelin I.Resultant derived fragment is called after SgI-29 in the present invention, and its total order is classified as: His AsnLys Gln Glu Gly Arg Asp His Asp Lys Ser Lys Gly His Phe His Arg Val Val Ile His His Lys Gly GlyLys Ala His.The theoretical molecular-weight average [M+H] of SgI-29+be 3377.74, determining molecular weight [M+H]+be 3377.17.Experimental result has proved that fully SgI-29 is hydrolyzed the back by people's semenogelin I and produces.
Embodiment 2
1, the preparation of human antibiotic peptide and separation and purification:
Present embodiment adopts the solid state chemistry synthesis method to carry out, and utilizes full-automatic polypeptide synthetic instrument to synthesize their complete sequence respectively, and the title of each synthetic antibacterial peptide and complete sequence amino acid primary structure thereof are as follows:
SgI-29(SEQ?ID?NO：1)：
His?Asn?Lys?Gln?Glu?Gly?Arg?Asp?His?Asp?Lys?Ser?Lys?Gly?His?Phe?His?Arg?Val?Val?Ile?HisHis?Lys?Gly?Gly?Lys?Ala?His
SgI-29R7K(SEQ?ID?NO：2)：
His?Asn?Lys?Gln?Glu?Gly?Lys?Asp?His?Asp?Lys?Ser?Lys?Gly?His?Phe?His?Arg?Val?Val?Ile?HisHis?Lys?Gly?Gly?Lys?Ala?His
SgI-25(SEQ?ID?NO：3)：
Lys?Gln?Glu?Gly?Arg?Asp?His?Asp?Lys?Ser?Lys?Gly?His?Phe?His?Arg?Val?Val?Ile?His?His?LysGly?Gly?Lys。
By the desalination of the anti-phase C18 column chromatography of HPLC, purifying.
2, the evaluation of human antibiotic peptide:
The human antibiotic peptide of purifying is identified its purity with the high-efficient liquid phase chromatogram HPLC method, and molecular weight determination adopts the fast atom bombardment mass spectroscopy(FABMS) method, measures the aminoacid sequence structure with automatic Protein Sequencer.
Embodiment 3
1, the expression of human antibiotic peptide SgI-29 gene in intestinal bacteria
According to known the 86th to the 112nd the gene order that is encoded into acquaintance's semenogelin I, it is cloned on the expression vector pMAL-p2X plasmid, transformed into escherichia coli DH5 α then, through IPTG abduction delivering MBP-SgI-29 fusion rotein in colibacillus periplasm, bacterium pericentral siphon Partial Protein is crossed the MBP affinity column after hypotonic processing, obtain purifying MBP-SgI-29 fusion rotein, after the FXa cutting, obtain antibacterial peptide SgI-29 again.
The high-fidelity pfu enzyme that uses among the embodiment, the T4DNA ligase enzyme is available from U.S. Promega company, restriction enzyme Xmn I, Hind III, affine resin (Amylose resin) and expression vector pMAL-p2X are available from Britain New England BioLabs company, Tryptones, yeast extract are available from Oxoid company, and acrylamide, methylene diacrylamide, Ammonium Persulfate 98.5, isopropyl-(IPTG) etc. are available from Sigma company.FXa is available from Novagen company.
People's seminal vesicle take from one 56 years old because of bladder urothelium cancer row bladder, prostate gland, seminal vesicle total resection male patient, pathologic finding confirms that seminal vesicle is not by tumor invading.The seminal vesicle that operation is downcut places liquid nitrogen to preserve immediately, up to extracting total RNA.
2, the extraction of total RNA and cDNA are synthetic
Total RNA adopts Qiangen company total RNA extraction reagent box to extract.The synthetic TAKALA company test kit that adopts of cDNA, the concrete operations by specification carries out.
3, design of primers and synthetic
According to the sequences Design primer of SgI gene, SgI-1 5 ' GGT TTT CCA AGC AAG ATG AAG 3 '; SgI-1R:5 ' AGG TGG TGT CAT CCA TGG ACC AAG 3 '; SgI-EX1 5 ' CAT AAT AAA CAAGAA GGC AGA GAC C 3 '; SgI52-EXR 5 ' CCT AAC AAG CTT TTA ATA TTG ACT GGATAT TCC 3 ' is synthesized by Beijing hundred victory companies that match.Wherein AAG CTT is the restriction enzyme site of HindIII, and the base CCTAAC of its front is the protection sequence.
4, SgI52 gene amplification and clone
With the cDNA that has obtained is masterplate, and adopting SgI-1 and SgI-1R is that primer carries out pcr amplification, condition: cDNA 1 μ l, 10 X buffer, 5 μ l, dNTP (10mM) 1 μ l, SgI-1 (20p/ μ l) 1 μ l, SgI-1R (20p/ μ l) 1 μ l, pfu 0.25 μ l, ddH2O 40.75 μ l.Pcr amplification condition: 94 ℃ of 2min; 92 ℃ of 15s, 50 ℃ of 30s, 72 ℃ of 1min, 35 circulations; 72 ℃ of 10min.PCR product row agarose gel electrophoresis reclaims test kit with the obvious band in 1.3Kb place with Tiangen DNA glue and carries out the DNA recovery.Do substrate with the DNA that reclaims, do primer with SgI-EX1 and SgI52-EXR and carry out pcr amplification SgI-52 gene fragment.Condition: the SgI DNA 0.5 μ l of recovery, 10 X buffer, 5 μ l, dNTP (2.5mM) 4 μ l, SgI-EX1 (20p/ μ l) 1 μ l, SgI52-EXR (20p/ μ l) 1 μ l, pfu 0.25 μ l, H2O 38.25 μ l.PCR expands condition once: 94 ℃ of 2min; 92 ℃ of 15s, 50 ℃ of 30s, 72 ℃ of 20s, 35 circulations; 72 ℃ of 2min.The PCR product finds near the 150bp obvious band is arranged through electrophoresis.The PCR product is cut through the HindIII enzyme, cuts the glue purification gene fragment.Adopt the pMAL-p2X plasmid in the test kit extracting e. coli jm109, cut plasmid with restriction endonuclease HindIII and XmnI, electrophoresis confirms.With the T4 ligase enzyme plasmid is connected with the SgI-52 gene that cuts with restriction endonuclease HindIII.4 ℃ are spent the night.The transformed competence colibacillus bacillus coli DH 5 alpha.Picking colony is identified, and is extracted the plasmid order-checking.
5, the abduction delivering of SgI-52 polypeptide
Incubated overnight has the pMAL-p2X plasmid bacillus coli DH 5 alpha of SgI-52 gene.The bacillus coli DH 5 α that adds 1/100 incubated overnight enters RB substratum 1000ml, 37 ℃ of 200rpm shake the about 2-3 of bacterium hour to O.D.600 be 0.5.Adding IPTG (final concentration is 0.3mM) and continue to cultivate and induce 3 hours, is contrast not add each recombinant plasmid transformed bacterial cultures of IPTG inductive.
6, recombinant protein detects and identifies
1 liter of bacterial cultures is collected bacterium in the centrifugal 10min of 4000g, with the resuspended bacterium of 30mM Tris-HCl+20%Sucrose pH8.0 (every g bacterium adds 80ml).It is 1mM that the EDTA that adds 0.5M makes final concentration, and room temperature was shaken 5-10 minute.Centrifugal 10 minutes of 4 ℃ of 8000g.MgSO4 with the ice-cold 5mM of 2.5ml is resuspended.Shook under the ice bath 10 minutes.Centrifugal 10 minutes of 4 ℃ of 8000g.Supernatant liquor is the protein of periplasmic expression.Add suitable albumen sample-loading buffer, carry out the SDS-PAGE electrophoresis after boiling 5min, and, determine that recombinant protein has or not expression through coomassie brilliant blue staining.With the X factor recombinant protein is excised from fusion rotein, carry out mass spectroscopy and sequencing.
Embodiment 4
Anti-microbial activity detects, reference literature method (Lehrer et al., 1991.Ultrasensitive assays for endogenousantimicrobial polypeptides.J.Immunol.Methods 137:167-173), adopt the double-deck punch method of agarose to measure minimal effective concentration MEC (Minimal Effective Concentration).Sample in the present embodiment adopts the solid phase method chemosynthesis, and the title of each synthetic antibacterial peptide and complete sequence amino acid primary structure thereof are seen embodiment 2.
Wherein, the nucleotide sequence of SgI-29 sees that accompanying drawing 6, aminoacid sequence see that the mass spectrum of accompanying drawing 7, synthetic human antibiotic peptide SgI-29 sees accompanying drawing 8.
The bottom culture medium prescription is: 1% low melting-point agarose (SigmaA6013), 0.3mg/ml Trypsin freeze (Oxoid product) and are dissolved in the 10mM pH7.4 Na2HPO4-NaH2PO4 damping fluid.Bottom substratum 20ml adds incubated overnight logarithmic phase bacterium (about 105-106CFU) respectively in the time of 42 ℃, make it evenly spread out cloth as bottom in diameter 76mm culture dish after shaking up.After waiting to solidify, beat the circular hole of 3mm on the bottom substratum, every hole adds the antibacterial peptide aqueous solution of 5 μ l different concns.37 ℃ hatch 3 hours after, on bottom, cover one deck nutrient agar medium (top layer substratum: 1%Sigma A6013 low melting-point agarose, be dissolved in the 10mM pH7.4 Na2HPO4-NaH2PO4 damping fluid 0.6mg/ml the Oxoid Trypsin freezes), 37 ℃ were continued to hatch 12-16 hour.Measure the transparent ring diameter of asepsis growth.The calculating of anti-microbial activity: the U=of anti-microbial activity unit (the diameter mm-3 of antibiotic ring) X10.Logarithmic value with antibacterial peptide concentration is an X-coordinate, and anti-microbial activity is that ordinate zou is made regression equation, and calculates the Cmin MEC of the antibacterial peptide of energy bacteria growing inhibiting.Bacterial isolates derives from No.1 Hospital Attached to Kunming Medical College, and this test repeats four times, averages result such as table 1.
The bacteriostatic activity of table 1. human antibiotic peptide SgI-29
| Microorganisms | Minimal effective concentration MEC (μ g/ml) | ||
| SgI-29 | ?SgI-29R7K | SgI-25 | |
| ?Escherichia?coli?ATCC?25922 ?Escherichia?coli?ML-3?5P ?Escherichia?coli?clinic?strain?1 ?Escherichia?coli?clinic?strain?2 ?Bacillus?pyocyaneus?ATCC?27853 ?Bacillus?pyocyaneus?CMCCB?10104 ?Bacillus?pyocyaneus?PA?01 ?Bacillus?pyocyaneus?clinic?strain ?Staphylococcus?aureus?ATCC?25923 ?Staphylococcus?aureus?ATCC?43300 | ?2.831 ?7.433 ?3.556 ?3.937 ?5.292 ?7.334 ?12.864 ?10.405 ?＞100 ?＞100 | 3.062 6.882 4.079 3.638 4.996 6.378 10.638 11.909 undetermined undetermineds | 5.361 10.231 6.823 7.231 11.734 15.634 18.885 25.362 undetermined undetermineds |
| ?Candida?albicans ATCC?10231 ?Pichia?pastoris?GS?115 | ?20.523 ?18.244 | 25.768 21.224 | ?30.665 ?24.315 |
Test the explanation of used bacterium and fungal bacterial strain:
Streptococcus aureus (Staphylococcus aureus) ATCC 43300 is methicillin resistant staphylococcus aureus ATCC type strains, and to penicillins, the beta-lactam resistance is to the vancomycin sensitivity.
Intestinal bacteria (Escherichia coli) ML-35P is an ammonia benzyl resistance type strain.
Intestinal bacteria (Escherichia coli) clinical drug-resistant strain 1 and 2 is the clinical separation strain that produces extended spectrum, to penicillin, 1 generation of cephalo, 2 generations, 3 generations and 4 generation resistance, to safe can, the aminoglycosides sensitivity.
Pseudomonas aeruginosa (Bacillus pyocyaneus) clinical drug-resistant strain is the multidrug resistance clinical separation strain, to the equal resistance of all kinds of microbiotic of present clinical use, comprises safe energy, MEM.
The Candida albicans of Mycophyta (Candida albicans) ATCC 10231 and pichia spp (Pichia pastoris) GS115 are type strain.
By table 1 as seen, synthetic human antibiotic peptide SgI-29 and amino acid replacement thereof and aminoacid deletion derivative have the effect of significant inhibition bacterium and fungal growth, can be used as antimicrobial material and are used to prepare the anti-microbial infection preparation.
Sequence table .SEQ
＜110〉Kunming Institute of Zoology, Chinese Academy of Sciences
＜120〉human antibiotic peptide and antimicrobial application thereof
<160>6
<210>1
<211>29
<212>PRT
＜213〉homo sapiens (Homo sapiens)
<400>1
His?Asn?Lys?Gln?Glu?Gly?Arg?Asp?His?Asp?Lys?Ser?Lys?Gly?His?Phe
1 5 10 15
His?Arg?Val?Val?Ile?His?His?Lys?Gly?Gly?Lys?Ala?His
20 25
<210>2
<211>29
<212>PRT
＜213〉artificial sequence
<400>2
His?Asn?Lys?Gln?Glu?Gly?Lys?Asp?His?Asp?Lys?Ser?Lys?Gly?His?Phe
1 5 10 15
His?Arg?Val?Val?Ile?His?His?Lys?Gly?Gly?Lys?Ala?His
20 25
<210>3
<211>25
<212>PRT
＜213〉artificial sequence
<400>3
Lys?Gln?Glu?Gly?Arg?Asp?His?Asp?Lys?Ser?Lys?Gly?His?Phe?His?Arg
1 5 10 15
Val?Val?Ile?His?His?Lys?Gly?Gly?Lys
20 25
<210>4
<211>87
<212>DNA
＜213〉homo sapiens (Homo sapiens)
<400>4
cataataaac?aagaaggcag?agaccatgat?aaatcaaaag?gtcattttca?cagggtagtt 60
atacaccata?aaggaggcaa?agctcat 87
<210>5
<211>87
<212>DNA
＜213〉artificial sequence
<400>5
cataataaac?aagaaggcaa?agaccatgat?aaatcaaaag?gtcattttca?cagggtagtt 60
atacaccata?aaggaggcaa?agctcat 87
<210>6
<211>75
<212>DNA
＜213〉artificial sequence
<400>6
aaacaagaag?gcaaagacca?tgataaatca?aaaggtcatt?ttcacagggt?agttatacac 60
cataaaggag?gcaaa 75
Claims (10)
1. isolating human antibiotic peptide is characterized in that described human antibiotic peptide has to be selected from the aminoacid sequence shown in the sequence table SEQ IDNO:1: His Asn Lys Gln Glu Gly Arg Asp His Asp Lys Ser Lys Gly HisPhe His Arg Val Val Ile His His Lys Gly Gly Lys Ala His.
2. substitute and have the antibacterial peptide of anti-microbial activity derived from the isolating human antibiotic peptide amino-acid residue of claim 1, it is characterized in that described antibacterial peptide has to be selected from the aminoacid sequence shown in the sequence table SEQ ID NO:2: His AsnLys Gln Glu Gly Lys Asp His Asp Lys Ser Lys Gly His Phe His Arg Val Val Ile His His LysGly Gly Lys Ala His.
3. derived from a plurality of aminoacid deletion of claim 1 and have the antibacterial peptide of anti-microbial activity, it is characterized in that described antibacterial peptide has to be selected from the aminoacid sequence shown in the sequence table SEQ ID NO:3: Lys Gln Glu Gly Arg AspHis Asp Lys Ser Lys Gly His Phe His Arg Val Val Ile His His Lys Gly Gly Lys.
4. the separation method of the described human antibiotic peptide of claim 1 is characterized in that separating antibacterial peptide and has the aminoacid sequence shown in the SEQ IDNO:1.
5. the preparation method of claim 1,2 and 3 described human antibiotic peptides and derivative thereof is characterized in that adopting mechanochemical method synthetic.
6. an isolating nucleotide sequence or its complementary sequence is characterized in that the described antibacterial peptide of described nucleotide sequence coded claim 1 to 3.
7. a construction is characterized in that described construction contains the described nucleotide sequence of claim 1 to 3.
8. a cell is characterized in that described cell contains the described peptide of claim 1 to 3, the described nucleotide sequence of claim 6 or the described construction of claim 7.
9. method for preparing the described antibacterial peptide of claim 1 to 3 is characterized in that this method comprises:
(1) under the condition that is fit to the described peptide expression of claim 1 to 3, cultivates the described cell of claim 8;
(2) isolate the described antibacterial peptide of claim 1 to 3.
10. the purposes of described human antibiotic peptide of claim 1 to 3 and derivative thereof is characterized in that: the application in the medicine of preparation anti-microbial infection of described antibacterial peptide and derivative thereof.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2007100663029A CN101168564B (en) | 2007-10-22 | 2007-10-22 | Human antibiotic peptide and use for derivative thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2007100663029A CN101168564B (en) | 2007-10-22 | 2007-10-22 | Human antibiotic peptide and use for derivative thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101168564A true CN101168564A (en) | 2008-04-30 |
| CN101168564B CN101168564B (en) | 2012-03-21 |
Family
ID=39389355
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2007100663029A Expired - Fee Related CN101168564B (en) | 2007-10-22 | 2007-10-22 | Human antibiotic peptide and use for derivative thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101168564B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102906105A (en) * | 2010-03-31 | 2013-01-30 | 诺瓦生命科学有限公司 | Compounds and their use |
| CN105994251A (en) * | 2016-06-20 | 2016-10-12 | 成都美强兽医技术服务有限公司 | Diluting and preserving solution for killing animal sperm viruses and bacteria |
| CN110438139A (en) * | 2019-07-04 | 2019-11-12 | 东北农业大学 | A method of antibacterial peptide T9W is prepared using Pichia yeast |
| CN112263712A (en) * | 2020-10-14 | 2021-01-26 | 中山大学附属第六医院 | Peritoneal repair material with antibacterial property and preparation method thereof |
-
2007
- 2007-10-22 CN CN2007100663029A patent/CN101168564B/en not_active Expired - Fee Related
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102906105A (en) * | 2010-03-31 | 2013-01-30 | 诺瓦生命科学有限公司 | Compounds and their use |
| CN102906105B (en) * | 2010-03-31 | 2017-05-10 | 诺瓦生命科学有限公司 | Compounds and their use |
| CN105994251A (en) * | 2016-06-20 | 2016-10-12 | 成都美强兽医技术服务有限公司 | Diluting and preserving solution for killing animal sperm viruses and bacteria |
| CN105994251B (en) * | 2016-06-20 | 2018-07-17 | 成都美强兽医技术服务有限公司 | A kind of dilution preservation liquid for killing animal semen virus and bacteria |
| CN110438139A (en) * | 2019-07-04 | 2019-11-12 | 东北农业大学 | A method of antibacterial peptide T9W is prepared using Pichia yeast |
| CN112263712A (en) * | 2020-10-14 | 2021-01-26 | 中山大学附属第六医院 | Peritoneal repair material with antibacterial property and preparation method thereof |
| CN112263712B (en) * | 2020-10-14 | 2022-04-29 | 中山大学附属第六医院 | Peritoneal repair material with antibacterial property and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101168564B (en) | 2012-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lai et al. | Antimicrobial peptides from skin secretions of Chinese red belly toad Bombina maxima | |
| Lee et al. | Clavanins, α‐helical antimicrobial peptides from tunicate hemocytes | |
| Cho et al. | Lumbricin I, a novel proline-rich antimicrobial peptide from the earthworm: purification, cDNA cloning and molecular characterization | |
| DIMARCQ et al. | Insect immunity: purification and characterization of a family of novel inducible antibacterial proteins from immunized larvae of the dipteran Phormia terranovae and complete amino‐acid sequence of the predominant member, diptericin A | |
| Lawyer et al. | Antimicrobial activity of a 13 amino acid tryptophan‐rich peptide derived from a putative porcine precursor protein of a novel family of antibacterial peptides | |
| US5550109A (en) | Inducible defensin peptide from mammalian epithelia | |
| AU633832B2 (en) | Novel antimicrobial peptide, compositions containing same and uses thereof | |
| CN101265296B (en) | Reptile cathelicidin antibiotic peptide and derivatives, and application thereof | |
| Sun et al. | A novel cathelicidin from Bufo bufo gargarizans Cantor showed specific activity to its habitat bacteria | |
| AU660433B2 (en) | Production and use of tracheal antimicrobial peptides | |
| KR101615551B1 (en) | Antimicrobial peptide from Protaetia brevitarsis seulensis larva and uses thereof | |
| Qi et al. | Molecular cloning, expression analysis and functional characterization of interleukin-22 in So-iny mullet, Liza haematocheila | |
| Yu et al. | A novel antimicrobial peptide from salivary glands of the hard tick, Ixodes sinensis | |
| Chen et al. | An antimicrobial peptide with antimicrobial activity against Helicobacter pylori | |
| CN101168564B (en) | Human antibiotic peptide and use for derivative thereof | |
| KR101764852B1 (en) | Antimicrobial peptide derived from Octopus variabilis and antimicrobial pharmaceutical composition containing the same | |
| Jin et al. | Characterization of antimicrobial peptides isolated from the skin of the Chinese frog, Rana dybowskii | |
| ES2808780T3 (en) | New antimicrobial peptides, their variants and uses | |
| Kim et al. | Purification and characterization of antimicrobial peptides from the skin secretion of Rana dybowskii | |
| EP0979831B1 (en) | Antibacterial peptides and antibacterial agents containing such peptides as an effective ingredient | |
| Huo et al. | Molecular characterization, antibacterial activity and mechanism analyzation of three different piscidins from black rockfish, Sebastes schlegelii | |
| Kim et al. | Bacterial expression of tenecin 3, an insect antifungal protein isolated from Tenebrio molitor, and its efficient purification | |
| JP2001517422A (en) | Isolated and recombinant antimicrobial peptides thrombosidine-1 (TC-1) and thrombosidine-2 (TC-2) or variants thereof | |
| Wang et al. | The novel antimicrobial peptides from skin of Chinese broad-folded frog, Hylarana latouchii (Anura: Ranidae) | |
| CN109021086B (en) | Antibacterial peptide cecropin A mutant and encoding gene, preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120321 Termination date: 20151022 |
|
| EXPY | Termination of patent right or utility model |